IGF1 and colitis: Additionally, oral administration of recombinant L. lactis expressing insulin-like growth factor I (IGF-I) improved intestinal damage and barrier integrity and reduced colonic MPO activity in DSS-induced colitis mice; however, when compared with wild-type probiotics, it only achieved better alleviation of the histological damage score [53].